NOT Entered
GN 3/13/05

I. AMENDMENT

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 44, 48, 52, 53, 57, and 62-64 are amended, and claim 47 is canceled.

1-43. (Canceled)

44. (Currently amended) A method of treating cancer comprising administering to a patient in need thereof:

(a) an admixture comprising a cancer or tumor antigen expressed by cells of the cancer to be treated and a microfluidized antigen formulation comprising:

(i) a stabilizing detergent,

(ii) a micelle-forming agent, and

(iii) a biodegradable and biocompatible oil,

said antigen formulation being formulated as a stable oil-in-water emulsion;

wherein said admixture is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient which is specific for the cancer or tumor antigen contained in said admixture, and

(b) a therapeutically effective amount of at least one agent which is capable of neutralizing, blocking, antagonizing, or down regulating the activity or preventing activation of transforming growth factor β (TGFβ) specifically, which agent is selected from the group consisting of an anti-TGFβ antibody, a TGFβR-fusion protein, a TGFβ analog, a TGFβ binding protein, and a TGFβR blocking antibody;

wherein the antigen-containing admixture and the at least one agent which is capable of neutralizing, blocking, antagonizing, or down regulating the activity or preventing activation of TGFβ are administered sequentially or concurrently, and in any order.

PAGE 4/12 * RCVD AT 2/28/2005 3:11:40 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/5 * DNIS:8729306 * CSID:9543775553 * DURATION (mm-ss):03-24